Willingness to use HIV pre-exposure prophylaxis among community-recruited, older people who inject drugs in Washington, DC
Irene Kuo(George Washington University), Alan E. Greenberg(Milken Institute), Jenevieve Opoku(Government of the District of Columbia), Manya Magnus(Milken Institute), Michael Kharfen(Government of the District of Columbia), Anthony Rawls(George Washington University), Halli Olsen(Milken Institute), James A. Peterson(George Washington University), Rudy Patrick(Milken Institute), Flora Hamilton(Family and Medical Counseling Service), Gregory Phillips(George Washington University)
Cited by 85
Related Papers
Understanding Structural Barriers to Accessing HIV Testing and Prevention Services Among Black Men Who Have Sex with Men (BMSM) in the United States
|AIDS and Behavior|2014|303
Correlates of HIV Acquisition in a Cohort of Black Men Who Have Sex with Men in the United States: HIV Prevention Trials Network (HPTN) 061
|PLoS ONE|2013|196
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
|The Lancet HIV|2020|177
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
|PLoS Medicine|2018|173
Routine HIV Screening in the Emergency Department Using the New US Centers for Disease Control and Prevention Guidelines
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2007|169